Atlantic City, NJ
10/11/2025 - 10/12/2025
8:00 am - 1:00 pm
Where: Tropicana Resort and Casino
Topics include: topics: pharmacy law & medication errors, pharmacists accountability with controlled substances
Atlantic City, NJ
HOTEL INFO: Please call us to assist with room reservation
THIS WEEKEND IN AC SATISFIES NEW JERSEY PHARMACISTS CE REQUIREMENTS FOR BOTH PHARMACY LAW AND OPIOID MEDICATIONS
Tropicana Resort & Casino
Group rate $149 Friday night and $249 Saturday nights single or double occupancy. Extra adult in room $25 per night. Max of 4 people in room.
www.caesars.com/tropicana-ac
Dr. Reginal D. Harris, JD, PharmD, RPh, CPh, cMTM
InfoSource Communications, LLC
Dr. Reginal Harris founded InfoSource Communications in 1999 to offer pharmacy consulting, staffing, and Joint Commission readiness for institutional, governmental, and managed care pharmacies. His exemplary practice as a Registered Pharmacist in Texas, Illinois, and Florida spanned over 22 years. In November 2019, the company recognized and now provides legal consultation, representation, and services to individuals, non-profit, for-profit, and governmental clients tailored to meet their administrative, legal, corporate, and leadership needs. Dr Harris is a Texas licensed attorney admitted to practice before all Texas courts, the Department of Veterans Affairs, Board of Veterans Appeals, U.S. Court of Appeals for Veterans Claims, U.S. District Court for the Southern District of Texas and the Western District of Texas. For more than 30 years, he has educated and mentored thousands of students while serving as clinical or adjunct faculty for Florida A&M University, Northwest Vista College, Nova Southeastern University, San Antonio College, Texas A&M University (Kingsville), Texas Southern University, University of Colorado (Aurora), University of Florida, and the University of the Incarnate World. He has authored five books, eight e-books, seven CD-ROM training programs, six legal articles, and an Amicus brief that was accepted by the U.S. Supreme Court (2017).
Saturday October 11, 2025
PHARMACY LAW & MEDICATION ERRORS 2025
ACPE# TBA
Objectives:
1. Discuss the legal aspects of incorporating Continuous Quality Improvements (CQI) into pharmacy practice operations using the “Root Cause Analysis” model to determine how a medication error occurred.
2. Discuss the legal aspects of incorporating CQI into pharmacy practice operations using the “Focus-PDSA” model to reduce the likelihood of medication errors occurring in the future.
3. Explain the legal benefits of using the Institute of Safe Medication Practices National Medication Reporting Program (ISMP MERP) and demonstrate how to use these free tools and resources to develop strategies that prevent medication errors.
4. Use case studies to apply legal aspects of CQI principles to determine the origination of various medication errors using the Root Cause Analysis model.
5. Use case studies to apply legal aspects of CQI principles that reduce the likelihood of medication errors occurring in the future by using the Focus-PDSA model.
———————————————————————————————————————————————————————————————-
Sunday October 12, 2025
PHARMACISTS ACCOUNTABILITY: PREVENTING REGULATORY VIOLATIONS WHEN RECEIVING, EVALUATING, DISPENSING, AND COUNSELING ON CONTROLLED SUBSTANCE PRESCRIPTIONS
ACPE# TBA
Objectives:
- Define common terms relating to pathology of opioid misuse and addiction and what steps pharmacists can take when dispensing and counseling at-risk patients taking a controlled substance.
- Describe how a state’s Prescription Drug Monitoring Program assists pharmacists when determining the validity, use, misuse, and abuse of controlled substances.
- Describe how recent changes in the Controlled Substances Act help pharmacists identify “red flags” when receiving and evaluating controlled substance prescriptions.
- Define the concept of Risk Evaluation & Mitigation Strategy (REMS) as an evidence-based approach of assessing patients with chronic pain who are initiated on opioid or other pain medications and how to calculate the morphine milligram equivalents.
- Utilize standardized scales and tools to document pain characteristics and to guide medication management decisions by comparing/contrasting “strengths v. weaknesses” and “specificity v. sensitivity” of the scales and tools.
- Utilize the FDA education blueprint as a tool to identify patients showing signs of addiction, abuse, misuse, or overuse of pain medications.
- Apply the REMS and/or FDA approach to develop a comprehensive, customized treatment plan for a patient initiated on an opioid analgesic or other pain medications.
- Document treatment recommendations using the S.O.A.P. format to reinforce patient-clinician responsibilities.—————————————————————————————————————————————————————————————————————————————-